RYTM Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of -39.02%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Geron Corp.'s return on equity of -29.65%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $141.57, signalling upside risk potential of 43.77%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 111.18%. Given that Geron Corp. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 2.005, which suggesting that the stock is 100.46% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.620, suggesting its less volatile than the S&P 500 by 38.038%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are larger than Geron Corp. quarterly revenues of $47.2M. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Geron Corp.'s net income of -$18.4M. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 35.95x versus 5.85x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 27.55%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $141.57, signalling upside risk potential of 43.77%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $151.84 which suggests that it could fall by -2.54%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Gilead Sciences, Inc..

Rhythm Pharmaceuticals, Inc. has a beta of 2.005, which suggesting that the stock is 100.46% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.03% to investors and pays a quarterly dividend of $0.79 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.9B. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 22.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 35.95x versus 6.65x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 20.83%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Johnson & Johnson's return on equity of 33.27%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $141.57, signalling upside risk potential of 43.77%. On the other hand Johnson & Johnson has an analysts' consensus of $231.25 which suggests that it could fall by -3.99%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

Rhythm Pharmaceuticals, Inc. has a beta of 2.005, which suggesting that the stock is 100.46% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.13% to investors and pays a quarterly dividend of $1.30 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Johnson & Johnson's net income of $5.1B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 35.95x versus 6.21x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -103.13% compared to Rhythm Pharmaceuticals, Inc.'s net margin of 34.4%. Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34% beat Eli Lilly & Co.'s return on equity of 106.26%.

Rhythm Pharmaceuticals, Inc. has a consensus price target of $141.57, signalling upside risk potential of 43.77%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 18.36%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Rhythm Pharmaceuticals, Inc. has a beta of 2.005, which suggesting that the stock is 100.46% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Rhythm Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Rhythm Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rhythm Pharmaceuticals, Inc. quarterly revenues are $51.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Rhythm Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rhythm Pharmaceuticals, Inc. is 35.95x versus 14.01x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.